Benitec Biopharma, which is developing gene therapies for hepatitis C based on RNA interference, filed on Monday with the SEC to raise up to $70 million in an initial public offering.
The company’s stock currently trades on the Australian Securities Exchange under the symbol BLT.
The Balmain, Australia-based company, which was founded in 1995, plans to list on the NASDAQ under the symbol BNTC. Benitec Biopharma initially filed confidentially on 5/4/2015. BMO Capital Markets is the sole bookrunner on the deal. No pricing terms were disclosed.